Corisma develops a catheter implanted circulatory assist device designed to treat patients suffering from advanced heart failure.
Corisma has raised $27.0M in total funding. The most recent round was Series A. The last funding was announced in August 2021.
Corisma's investors include Propel(X), China Grand Pharmaceutical and Healthcare Holdings.
Corisma is headquartered in Bethany, United States.
Corisma develops a catheter implanted circulatory assist device designed to treat patients suffering from advanced heart failure.
Corisma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Corisma — Funding & Investors." VCBacked, August 30, 2021, https://www.vcbacked.co/company/corisma. Accessed August 16, 2026.
VCBacked. (2021). Corisma — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/corisma
{{cite web |title=Corisma — Funding & Investors |url=https://www.vcbacked.co/company/corisma |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated